Welcome to SelfCare

Editorial Board: Professor R W Soller, Professor P Noyce, Dr S G Mann,
Dr J D Irvin, Dr R P Juhl, Dr J Raine, Professor A Blenkinsopp, Dr D B Nash.

In this issue:

... an opinion paper proposes extending the reach of self-care into urinary incontinence, a hidden problem with many sufferers unaware of the treatment options available. Also on a urological theme, an original article describing a survey into pharmacists' attitudes surrounding the availability of tamsulosin as a pharmacy medicine for men with symptoms of benign prostatic hyperplasia. And finally a comment from the managing editor of SelfCare in this final issue of Volume 2.


Current Issue - Volume 2: Issue 6; Pages 151 - 165

Displaying articles 5 of 5

  • Page
  •  
  • 1
  •  

Editor's Note

Note From the Managing Editor of SelfCare. SelfCare 2011;2(6):151

Free Text

+

UK Community Pharmacists Experiences on Over-the-Counter Tamsulosin

by Ahmed S, Rutter P M

Ahmed S, Rutter P M. UK Community Pharmacists Experiences on Over-the-Counter Tamsulosin. SelfCare 2011;2(6):152-159

In the UK, government policy toward self-care now supports the management of some long-term conditions. In 2004, simvastatin was switched to P access for people who have a moderate risk of coronary heart disease. This deregulation met with opposition from pharmacists due to concern over patient management and the increased workload burden envisaged around training and record keeping. In 2010, tamsulosin was reclassified for the treatment of urinary symptoms of benign prostatic hyperplasia (BPH); the first medicine since simvastatin to be marketed for a non self-limiting condition. This study aimed to explore community pharmacist’s early experiences with the supply of non-prescription tamsulosin.

Article

+

Self Care in Urinary Incontinence

by Spinks J

Spinks J. Self Care in Urinary Incontinence. SelfCare 2011;2(6):160-166

Urinary incontinence and its associated urinary symptoms have a major impact on the lives of those who suffer from them. The prevalence of the condition is high with estimates of as many as one in three women over the age of 181. Despite this, only a small minority of sufferers are known to health services with only 20% of people with the condition receiving active treatment1. The impact on quality of life for those with the condition is large. There are high levels of fear and anxiety associated with the symptoms suffered, together with a social stigma which leaves sufferers reluctant to discuss the problem. This reluctance applies even to those who could help, such as their GP.

Opinion

+

SelfCare Focus

A selection of newly published papers on self care from the worldwide literature

Every week, we will provide a brief summary and a link to the published abstract of newly published papers selected from the worldwide literature as being of particular interest to the SelfCare community.

Free Text

+

Displaying articles 5 of 5

  • Page
  •  
  • 1
  •